From basic mechanisms to therapeutic perspectives in cluster headache

Curr Opin Neurol. 2022 Jun 1;35(3):336-342. doi: 10.1097/WCO.0000000000001055.

Abstract

Purpose of review: The pathophysiological understanding of cluster headache has evolved significantly over the past years. Although it is now well known that the trigeminovascular system, the parasympathetic system and the hypothalamus play important roles in its pathomechanism, we increasingly understand the functional role several neurotransmitters and hormones play in the communication between these structures.

Recent findings: This work will give an overview of the current understanding of the role of calcitonin gene-related peptide, vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, melatonin and orexins in cluster headache. On the basis of recent evidence, this study will also review the relevance of the monoclonal calcitonin gene-related peptide antibody galcanezumab as well as the sleep-regulating hormone melatonin in the treatment of cluster headache.

Summary: Herein, we aim to review the basic mechanisms implicated in the pathophysiology of cluster headache and how the increased mechanistic understanding may lead to the discovery of novel therapeutic targets.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Calcitonin Gene-Related Peptide
  • Cluster Headache* / drug therapy
  • Humans
  • Melatonin* / therapeutic use
  • Pituitary Adenylate Cyclase-Activating Polypeptide / therapeutic use
  • Vasoactive Intestinal Peptide / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Vasoactive Intestinal Peptide
  • Calcitonin Gene-Related Peptide
  • Melatonin